An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
Acadia Pharmaceuticals has announced that Health Canada has accepted the New Drug Submission (NDS) for trofinetide for the treatment of Rett syndrome, granting Priority Review. The submission is supported by positive Phase 3 study results, showing significant improvements in patients. If approved, trofinetide will be the first treatment option for Rett syndrome in Canada.
Acadia Pharmaceuticals ha annunciato che Health Canada ha accettato la Nuova Proposta di Medicinale (NDS) per il trofinetide per il trattamento della sindrome di Rett, concedendo una Revisione Prioritaria. La proposta è supportata dai risultati positivi dello studio di Fase 3, che mostrano significativi miglioramenti nei pazienti. Se approvato, il trofinetide sarà la prima opzione di trattamento per la sindrome di Rett in Canada.
Acadia Pharmaceuticals ha anunciado que Health Canada ha aceptado la Solicitud de Nuevo Medicamento (NDS) para trofinetide destinado al tratamiento del síndrome de Rett, otorgando una Revisión Prioritaria. La solicitud cuenta con el respaldo de los resultados positivos del estudio de Fase 3, que muestran mejoras significativas en los pacientes. Si se aprueba, trofinetide sería la primera opción de tratamiento para el síndrome de Rett en Canadá.
아카디아 파마슈티컬스는 캐나다 보건부가 레트 증후군 치료를 위한 트로피네티드 신약 허가 신청(NDS)을 받아들여 우선 검토를 부여했다고 발표했습니다. 제출된 자료는 3단계 연구 결과를 바탕으로 하며, 환자들의 상당한 개선을 보여주고 있습니다. 승인될 경우, 트로피네티드는 캐나다에서 레트 증후군을 위한 첫 번째 치료 옵션이 될 것입니다.
Acadia Pharmaceuticals a annoncé que Santé Canada a accepté la Soumission de Nouveau Médicament (NDS) pour le trofinetide pour le traitement du syndrome de Rett, accordant une Révision Prioritaire. La soumission est appuyée par les résultats positifs de l'étude de phase 3, montrant des améliorations significatives chez les patients. Si approuvé, le trofinetide sera la première option de traitement du syndrome de Rett au Canada.
Acadia Pharmaceuticals hat bekannt gegeben, dass Health Canada die Neue Arzneimittelzulassung (NDS) für Trofinetid zur Behandlung des Rett-Syndroms akzeptiert hat und eine Prioritätsprüfung gewährt. Die Einreichung wird durch positive Ergebnisse der Phase-3-Studie unterstützt, die bedeutende Verbesserungen bei den Patienten zeigen. Wird es genehmigt, wäre Trofinetid die erste Behandlungsoption für das Rett-Syndrom in Kanada.
Positive
None.
Negative
None.
Insights
The acceptance of Acadia Pharmaceuticals' New Drug Submission for trofinetide by Health Canada is a pivotal regulatory milestone, potentially unlocking a new market for the company. With Rett syndrome being a rare condition, treatment options are limited and the advent of trofinetide may represent a substantial advancement. Historically, the approval of novel treatments for rare diseases has often been met with a positive response from investors, as these typically command high prices and can be granted market exclusivity, leading to increased revenues. Additionally, the designation of Priority Review suggests that there may be a significant need for this therapy, potentially accelerating the timeline to market. Investors should observe the company's guidance on anticipated commercialization strategies and revenue projections following potential approval.
As a new treatment avenue, trofinetide's impact on Rett syndrome could be substantial, given the clinical effectiveness demonstrated in the LAVENDER study. The therapy's success in meeting both co-primary endpoints indicates a positive benefit/risk profile. For investors, drug efficacy and safety are critical factors that can influence a drug's adoption rate and market penetration. The acceptance of the NDS is a significant step, but the scalability of production, the actual drug pricing and reimbursement will be important components of the drug's success. Stakeholders should monitor ongoing clinical development and any potential partnerships or collaborations that could streamline the commercialization process.
The rare disease market has been growing due to increased awareness and supportive regulatory frameworks. In Canada, Rett syndrome affects a relatively small patient population, but the potential approval of trofinetide could serve as a precedent for future drug approvals within this category. The investors' focus should include examining the size of the affected population and potential competitors in the space. Understanding the nuances of the rare disease market, such as patient access, physician awareness and advocacy group support, is important for evaluating the long-term commercial potential of trofinetide. Moreover, the fact that trofinetide is already approved in the United States provides a blueprint for its commercial viability.
SAN DIEGO--(BUSINESS WIRE)--
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Health Canada has accepted its New Drug Submission (NDS) for trofinetide for the treatment of Rett syndrome, a rare neurodevelopmental disorder. Health Canada has granted Priority Review for Acadia’s submission.
“Rett syndrome is a profoundly debilitating and complex neurodevelopmental disorder that presents differently across patients and can lead to an array of unpredictable symptoms,” said Pamela di Cenzo, Vice President, General Manager, Rare Disease, Canada at Acadia. “If granted marketing authorization, trofinetide will be the first option available to treat Rett syndrome in Canada.”
Health Canada grants Priority Review for drug submissions intended for the treatment, prevention, or diagnosis of serious, life-threatening, or severely debilitating illnesses or conditions for which there is substantial evidence of clinical effectiveness that the drug addresses an unmet medical need or provides a benefit/risk profile that is improved over existing therapies.
“O.R.S.A. is pleased that Health Canada has granted Priority Review for this promising treatment which, if approved, would be a significant step forward in addressing the unmet medical needs of Canadians living with Rett syndrome,” said Sabrina Millson, President of the Ontario Rett Syndrome Association (O.R.S.A.). “Our community of patients, caregivers and supporters are excited at the prospect of having a treatment option for Rett syndrome.”
The Health Canada filing is supported by results from the positive pivotal Phase 3 LAVENDER™ study evaluating the efficacy and safety of trofinetide versus placebo in 187 girls and young women with Rett syndrome. The co-primary endpoints were change from baseline in the Rett Syndrome Behaviour Questionnaire (RSBQ) total score, a caregiver assessment, and Clinical Global Impression–Improvement (CGI-I) scale score, clinician perspective, at week 12; both were statistically significant. The key secondary endpoint measuring improvements in communication was also statistically significant. Trofinetide has been approved for the treatment of Rett syndrome in adult and pediatric patients two years of age and older in the United States, and it is not currently authorized for sale in Canada for the treatment of Rett syndrome.
About Rett Syndrome
Rett syndrome is a rare genetic neurodevelopmental disorder that occurs primarily in females following a near normal development in the first two years of life.1,2 It is caused by mutations on the X chromosome on a gene called MECP2.3 Rett syndrome is a complex and multisystem disorder that causes profound impairment to central nervous system (CNS) function, including loss of communication skills, purposeful hand use, gait abnormalities, and stereotypic hand movements such as hand wringing/squeezing, clapping/tapping, mouthing and washing/rubbing automatisms.2
Rett syndrome occurs worldwide in approximately one of every 10,000 to 15,000 female births.4 In Canada, prevalence of Rett syndrome is estimated to be 600 to 900 patients.5 Children with Rett syndrome experience a period of developmental regression between 18-30 months of age, which is typically followed by a plateau period lasting years to decades.1-3 Rett syndrome is diagnosed based on clinical evaluation, typically by about three years of age.2,6
About Acadia Pharmaceuticals Inc.
Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized in the United States the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only FDA-approved drug for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on Prader-Willi syndrome, Alzheimer’s disease psychosis and multiple other programs targeting neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at Acadia.com and follow us on LinkedIn and Twitter.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact and can be identified by terms such as “intends,” “may,” “will,” “should,” “can,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “potential” and similar expressions (including the negative thereof) intended to identify forward-looking statements. Forward-looking statements contained in this press release, include, but are not limited to, statements about: (i) the potential approval of trofinetide as the first option in Canada for the treatment of Rett Syndrome, (ii) the efficacy and safety profile of trofinetide for patients with Rett Syndrome, (iii) market acceptance in Canada, including the importance of trofinetide for the treatment of Rett Syndrome, if approved, for Rett patients or families with patients with Rett Syndrome and (iv) the ability for trofinetide to address the unmet medical needs of Canadians living with Rett syndrome. Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions, and other factors that may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. Such risks, uncertainties, assumptions and other factors include, but are not limited to: the ability for trofinetide to deliver efficacious and safe results to patients, if approved, our dependency on the continued successful commercialization of Daybue™ in the United States, where it is approved, our ability to obtain regulatory approval of trofinetide in Canada and other jurisdictions outside the United States, our ability to protect and enhance our intellectual property; and our ability to continue to stay in compliance with applicable laws and regulations. Given the risks and uncertainties, you should not place undue reliance on these forward-looking statements. For a discussion of these and other risks, uncertainties, assumptions, and other factors that may cause our actual results, performance or achievements to differ, please refer to our annual report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission on February 28, 2024, as well as our subsequent filings with the Securities and Exchange Commission from time to time. The forward-looking statements contained herein are made as of the date hereof, and we undertake no obligation to update them after this date, except as required by law.
References
1 Fu et al. Consensus guidelines on managing Rett syndrome across the lifespan. BMJ Paediatrics Open. 2020;4:1-14.
2 Neul JL, Kaufmann WE, Glaze DG, et al. Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol. 2010;68(6):944-950.
3 Amir RE, Van den Veyver IB, Wan M, et al. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet. 1999; 23(2):185-188.
4 May DM, Neul JL, Satija A, et al. Real-world clinical management of individuals with Rett syndrome: a physician survey. J of Med Econ. 26(1), 1570–1580.
5 Acadia Pharmaceuticals Inc. Data on File. Canada prevalence of Rett syndrome. February 2024.
6 Tarquinio DC, Hou W, Neul JL, et al. Age of Diagnosis in Rett Syndrome: Patterns of Recognition Among Diagnosticians and Risk Factors for Late Diagnosis. Pediatric Neurology. 2015;52:585-591.
Media Contact:
Acadia Pharmaceuticals Inc.
Deb Kazenelson
(818) 395-3043
media@acadia-pharm.com
Investor Contact:
Acadia Pharmaceuticals Inc.
Al Kildani
(858) 261-2872
ir@acadia-pharm.com
Acadia Pharmaceuticals Inc.
Jessica Tieszen
(858) 261-2950
ir@acadia-pharm.com
Source: Acadia Pharmaceuticals Inc.
FAQ
What did Acadia Pharmaceuticals announce regarding trofinetide and Rett syndrome?
Acadia Pharmaceuticals announced that Health Canada has accepted the New Drug Submission (NDS) for trofinetide for the treatment of Rett syndrome, granting Priority Review.
What is the significance of Health Canada granting Priority Review for Acadia's submission?
Health Canada grants Priority Review for drug submissions intended for the treatment, prevention, or diagnosis of serious, life-threatening, or severely debilitating illnesses. This indicates that trofinetide addresses an unmet medical need or provides an improved benefit/risk profile over existing therapies.
What study results support the Health Canada filing for trofinetide?
The filing is supported by results from the positive pivotal Phase 3 LAVENDER™ study, showing significant improvements in the Rett Syndrome Behaviour Questionnaire (RSBQ) total score and the Clinical Global Impression–Improvement (CGI-I) scale score in patients with Rett syndrome.
Has trofinetide been approved for the treatment of Rett syndrome in Canada?
Trofinetide has not been authorized for sale in Canada for the treatment of Rett syndrome. It has been approved for use in adult and pediatric patients two years of age and older in the United States.
